Wedbush Reiterates Outperform on Hemab Therapeutics Hldgs, Maintains $55 Price Target

Benzinga Newsdesk www.benzinga.com Positive 41.0%

Neg 0% Neu 0% Pos 41%

Wedbush analyst David Nierengarten reiterates Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Outperform and maintains $55 price target.